Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pertti J Neuvonen

Showing results (81-90 of 192) with videos related to

Pageof 20
Sort By:
Pharmacogenetics and Genomics|November 16, 2012
SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskirenTuija Tapaninen, Tiina Karonen, Janne T Backman, et al.
British Journal of Clinical Pharmacology|January 5, 2006
Effect of rifampicin on the pharmacokinetics of pioglitazoneTiina Jaakkola, Janne T Backman, Mikko Neuvonen, et al.
European Journal of Clinical Pharmacology|November 24, 2011
Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrationsTiina Karonen, Jouko Laitila, Mikko Niemi, et al.
Annals of Emergency Medicine|September 28, 2010
Intravenous lipid emulsion sequesters amiodarone in plasma and eliminates its hypotensive action in pigsTomohisa Niiya, Erik Litonius, Liisa Petäjä, et al.
British Journal of Clinical Pharmacology|September 11, 2008
Shift of statin use towards the elderly in 1995-2005: a nation-wide register study in FinlandPäivi Ruokoniemi, Arja Helin-Salmivaara, Timo Klaukka, et al.
European Journal of Clinical Pharmacology|May 4, 2006
Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazoneTiina Jaakkola, Janne T Backman, Mikko Neuvonen, et al.
Pharmacology, Biochemistry, and Behavior|January 15, 2009
Reduced benzodiazepine tolerance, but increased flumazenil-precipitated withdrawal in AMPA-receptor GluR-A subunit-deficient miceTeemu Aitta-Aho, Olga Y Vekovischeva, Pertti J Neuvonen, et al.
Basic & Clinical Pharmacology & Toxicology|June 27, 2015
Drug-Related Inadvertent Deaths in a University Hospital--A Declining TrendOuti Lapatto-Reiniluoto, Laura Patinen, Mikko Niemi, et al.
British Journal of Clinical Pharmacology|August 29, 2006
Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjectsJanne T Backman, Marjo J Karjalainen, Mikko Neuvonen, et al.
British Journal of Clinical Pharmacology|March 18, 2004
The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjectsMikko Niemi, Lauri I Kajosaari, Mikko Neuvonen, et al.
Pageof 20

Showing results (81-90 of 192) with videos related to

Sort By:
Pageof 20
Pharmacogenetics and Genomics|November 16, 2012
SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskirenTuija Tapaninen, Tiina Karonen, Janne T Backman, et al.
British Journal of Clinical Pharmacology|January 5, 2006
Effect of rifampicin on the pharmacokinetics of pioglitazoneTiina Jaakkola, Janne T Backman, Mikko Neuvonen, et al.
European Journal of Clinical Pharmacology|November 24, 2011
Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrationsTiina Karonen, Jouko Laitila, Mikko Niemi, et al.
Annals of Emergency Medicine|September 28, 2010
Intravenous lipid emulsion sequesters amiodarone in plasma and eliminates its hypotensive action in pigsTomohisa Niiya, Erik Litonius, Liisa Petäjä, et al.
British Journal of Clinical Pharmacology|September 11, 2008
Shift of statin use towards the elderly in 1995-2005: a nation-wide register study in FinlandPäivi Ruokoniemi, Arja Helin-Salmivaara, Timo Klaukka, et al.
European Journal of Clinical Pharmacology|May 4, 2006
Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazoneTiina Jaakkola, Janne T Backman, Mikko Neuvonen, et al.
Pharmacology, Biochemistry, and Behavior|January 15, 2009
Reduced benzodiazepine tolerance, but increased flumazenil-precipitated withdrawal in AMPA-receptor GluR-A subunit-deficient miceTeemu Aitta-Aho, Olga Y Vekovischeva, Pertti J Neuvonen, et al.
Basic & Clinical Pharmacology & Toxicology|June 27, 2015
Drug-Related Inadvertent Deaths in a University Hospital--A Declining TrendOuti Lapatto-Reiniluoto, Laura Patinen, Mikko Niemi, et al.
British Journal of Clinical Pharmacology|August 29, 2006
Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjectsJanne T Backman, Marjo J Karjalainen, Mikko Neuvonen, et al.
British Journal of Clinical Pharmacology|March 18, 2004
The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjectsMikko Niemi, Lauri I Kajosaari, Mikko Neuvonen, et al.
Pageof 20